Vilazodone: A Review in Major Depressive Disorder in Adults

Drugs

Volumn 75, Issue 16, 2015, Pages 1915-1923

  McCormack, Paul L ^a  

^a Springer ^*  (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VILAZODONE; ANTIDEPRESSANT AGENT;

ABDOMINAL PAIN; ADULT; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; FLATULENCE; HEADACHE; HUMAN; INCREASED APPETITE; INSOMNIA; MAJOR DEPRESSION; MAXIMUM PLASMA CONCENTRATION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; NONHUMAN; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESSNESS; REVIEW; SCORING SYSTEM; SEXUAL DYSFUNCTION; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT INDICATION; UNPLEASANT DREAM; VOLUME OF DISTRIBUTION; VOMITING; XEROSTOMIA; DEPRESSIVE DISORDER, MAJOR; DRUG INTERACTION;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG INTERACTIONS; HUMANS; VILAZODONE HYDROCHLORIDE;

EID: 84946214661     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-015-0490-y     Document Type: Review

References (40)

1. World Health Organization. Global burden of mental disorders and the need for a comprehensive, coordinated response from health and social sectors at the country level. 2011. http://apps.who.int/gb/ebwha/pdf-files/EB130/B130-9-en.pdf. Accessed 8 Oct 2015.
2. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095-105.
3. Kessler RC, Birnbaum H, Bromet E, et al. Age differences in major depression: results from the National Comorbidity Survey Replication (NCS-R). Psychol Med. 2010;40(2):225-37.
4. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR D report. Am J Psychiatry. 2006;163(11):1905-17.
5. Trivedi MH, Lin EHB, Katon WJ. Consensus recommendations for improving adherence, self-management, and outcomes in patients with depression. CNS Spectr. 2007;12(8 Suppl 13):1-27.
6. Hirschfeld RMA. The epidemiology of depression and the evolution of treatment. J Clin Psychiatry. 2012;73(Suppl 1):5-9.
7. Chang T, Fava M. The future of psychopharmacology of depression. J Clin Psychiatry. 2010;71(8):971-5.
8. Moret C, Isaac M, Briley M. Problems associated with long-term treatment with selective serotonin reuptake inhibitors. J Psychopharmacol (Oxf). 2009;23(8):967-74.
9. Uppal A, Singh A, Gahtori P, et al. Antidepressants: current strategies and future opportunities. Curr Pharm Des. 2010;16(38):4243-53.
10. Rocha FL, Fuzikawa C, Riera R, et al. Combination of antidepressants in the treatment of major depressive disorder: a systematic review and meta-analysis. J Clin Psychopharmacol. 2012;32(2):278-81.
11. Whale R, Terao T, Cowen P, et al. Pindolol augmentation of serotonin reuptake inhibitors for the treatment of depressive disorder: a systematic review. J Psychopharmacol (Oxf). 2010;24(4):513-20.
12. US FDA. Viibryd (vilazodone hydrochloride): US prescribing information. 2015. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/. Accessed 8 Oct 2015.
13. Frampton JE. Vilazodone: in major depressive disorder. CNS Drugs. 2011;25(7):615-27.
14. Wang SM, Han C, Lee SJ, et al. Vilazodone for the treatment of major depressive disorder: focusing on its clinical studies and mechanism of action. Psychiatry Investig. 2015;12(2):155-63.
15. Pierz KA, Thase ME. A review of vilazodone, serotonin, and major depressive disorder. Prim Care Companion CNS Disord. 2014;16(1). doi: 10.4088/PCC.13r01554.
16. Oosting R, Chan JSW, Olivier B, et al. Switching from paroxetine to vilazodone significantly reduced sexual side effects in male rats [abstract no. M27 plus poster]. In: 53rd Annual Meeting of the American College of Neuropsychopharmacology; 2014.
17. Choi YK, Oosting RS, Banerjee P, et al. Differential effects of vilazodone, citalopram, and paroxetine on serotonin transporters and receptors [abstract no. W185 plus poster]. In: 52nd Annual Meeting of the American College of Neuropsychopharmacology; 2013.
18. Khariton T, Bergstrand M, Plan E, et al. A population PKPD model for Changes in Sexual Function Questionnaire (CSFQ) in patients with major depressive disorder (MDD) treated with vilazodone or placebo [abstract no. T-032 plus poster]. J Pharmacokinet Pharmacodyn. 2014;41(1 Suppl):S53-54.
19. Clayton A, Durgam S, Mathews M, et al. Effects of vilazodone on sexual functioning in healthy adults: results from a randomized, double-blind, placebo- and active-controlled study [abstract no. MD-24]. In: US Psychiatric & Mental Health Congress; 2015.
20. Edwards J, Sperry V, Adams MH, et al. Vilazodone lacks proarrhythmogenic potential in healthy participants: a thorough ECG study. Int J Clin Pharmacol Ther. 2013;51(6):456-65.
21. Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review (vilazodone). 2010. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2011/022567Orig1s000TOC.cfm. Accessed 8 Oct 2015.
22. Boinpally R, Alcorn H, Adams MH, et al. Pharmacokinetics of vilazodone in patients with mild or moderate renal impairment. Clin Drug Investig. 2013;33(3):199-206.
23. Boinpally R, Henry D, Gupta S, et al. Pharmacokinetics and safety of vilazodone in hepatic impairment. Am J Ther. 2015;22(4):269-77.
24. Boinpally R, Gad N, Gupta S, et al. Influence of CYP3A4 induction/inhibition on the pharmacokinetics of vilazodone in healthy subjects. Clin Ther. 2014;36(11):1638-49.
25. Rickels K, Athanasiou M, Robinson DS, et al. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(3):326-33.
26. Khan A, Cutler AJ, Kajdasz DK, et al. A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. J Clin Psychiatry. 2011;72(4):441-7.
27. Croft HA, Pomara N, Gommoll C, et al. Efficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2014;75(11):e1291-8.
28. Mathews M, Gommoll C, Chen D, et al. Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial. Int Clin Psychopharmacol. 2015;30(2):67-74.
29. Citrome L, Gommoll CP, Tang X, et al. Evaluating the efficacy of vilazodone in achieving remission in patients with major depressive disorder: post-hoc analyses of a phase IV trial. Int Clin Psychopharmacol. 2015;30(2):75-81.
30. Robinson DS, Kajdasz DK, Gallipoli S, et al. A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder. J Clin Psychopharmacol. 2011;31(5):643-6.
31. Clayton AH, Gommoll C, Chen D, et al. Sexual dysfunction during treatment of major depressive disorder with vilazodone, citalopram, or placebo: results from a phase IV clinical trial. Int Clin Psychopharmacol. 2015;30(4):216-23.
32. Edwards J, Durgam S, Chen D, et al. Post hoc analyses of suicidality in clinical trials of vilazodone in adults with major depressive disorder [abstract no. 41 plus poster]. In: 168th American Psychiatric Association Annual Meeting; 2015.
33. American Psychiatric Association. Treating major depressive disorder: a quick reference guide. 2010. http://psychiatryonline.org/guidelines. Accessed 8 Oct 2015.
34. Hellerstein DJ, Flaxer J. Vilazodone for the treatment of major depressive disorder: an evidence-based review of its place in therapy. Core Evid. 2015;10:49-62.
35. Blier P, Gobbi G, Turcotte JE, et al. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol. 2009;19(7):457-65.
36. Blier P, Ward HE, Tremblay P, et al. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry. 2010;167(3):281-8.
37. Nelson JC, Mazure CM, Jatlow PI, et al. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry. 2004;55(3):296-300.
38. Nelson JC, Pikalov A, Berman RM. Augmentation treatment in major depressive disorder: focus on aripiprazole. Neuropsychiatr Dis Treat. 2008;4(5):937-48.
39. Rush AJ, Trivedi MH, Stewart JW, et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry. 2011;168(7):689-701.
40. Zhou Z-Y, Sun S, Chopra P, et al. Health resource use and costs of vilazodone and other selective serotonin reuptake inhibitors in treating major depressive disorder. J Med Econ. 2015. doi: 10.3111/13696998.2015.1061534.